Lynn Health Science Institute | Lynn Institute of the Ozarks

Research site

(Unclaimed)

Location

6209 W. 12th Street, Suite B, Little Rock, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Tanezumab

Diclofenac

K-877

Triglyceride

Fesoterodine

Elagolix

PF-06480605

Ruxolitinib

Tranexamic Acid

Metronidazole

Parent organization

This site is a part of Lynn Health Science Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 41 total trials

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

Enrolling

Sickle Cell Disease

Drug: Osivelotor

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting

COVID-19

Biological: mRNA-1273.222

Biological: mRNA-1283.222

Locations recently updated

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling

Atopic Dermatitis

Drug: Ruxolitinib Cream

Drug: Vehicle Cream

Status recently updated

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Not yet enrolling

Enrolling

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (EURELIA2)

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling

Hyperuricemia

Tophi

Drug: Allopurinol

Drug: Tigulixostat